What complications can occur with intrapleural fibrinolytic therapy (urokinase, alteplase, streptokinase) in a breast cancer patient with malignant loculated pleural effusion and lung metastases?

Complications of Intrapleural Fibrinolytic Therapy

Intrapleural fibrinolytic therapy (urokinase, alteplase, streptokinase) carries a primary risk of pleural hemorrhage, which can be life-threatening, along with less serious complications including chest pain, fever, and allergic reactions including rare fatal anaphylaxis.

Major Complications

Hemorrhage (Most Serious)

Bleeding is the most frequent and potentially fatal complication of fibrinolytic therapy 1. In your breast cancer patient with lung metastases, this risk is particularly concerning:

• Fatal hemorrhage has been reported, including intracranial and retroperitoneal bleeding 1
• Pleural hemorrhage occurs in approximately 3-8.5% of patients receiving intrapleural fibrinolytics 2, 3
• In controlled trials of urokinase for pulmonary embolism, bleeding causing ≥5% hematocrit decrease occurred in 37% (52/141) of patients 1
• Life-threatening pleural hemorrhage requiring emergency thoracotomy has been documented 4

The bleeding risk is particularly elevated in patients with:

• Concurrent anticoagulation (though coagulation parameters may not predict bleeding) 3
• Recent surgery or procedures
• Coagulopathy or thrombocytopenia
• Vascular tumor involvement (relevant in metastatic disease)

Anaphylaxis and Severe Allergic Reactions

Rare cases of fatal anaphylaxis have been reported with urokinase 1. Other allergic manifestations include:

• Bronchospasm
• Orolingual edema
• Urticaria and skin rash
• Pruritus

Infusion Reactions

These typically occur within one hour of beginning infusion 1 and include:

• Fever and/or chills/rigors
• Hypoxia and cyanosis
• Dyspnea and tachycardia
• Hypotension or hypertension
• Back pain, nausea, vomiting

Minor Complications

Common but Manageable

• Chest pain: Most frequent minor complication, occurring in 40-60% of patients 5, 6
• Fever: Second most common, generally low-grade and transient 6, 7
• These reactions generally respond to discontinuation and/or symptomatic treatment 1

Rare but Serious Complications

Cholesterol Embolization

Cholesterol embolism is rare but potentially lethal 1. Clinical features include:

• Livedo reticularis and "purple toe" syndrome
• Acute renal failure
• Gangrenous digits
• Myocardial or cerebral infarction
• Bowel infarction

Other Documented Complications

From post-marketing surveillance and clinical trials 1:

• Cardiac arrest
• Cerebrovascular accident
• Pulmonary edema
• Reperfusion ventricular arrhythmias
• Vascular embolization (cerebral and distal)

Special Considerations for Malignant Pleural Effusion

In the context of malignant loculated pleural effusion, the evidence shows limited clinical benefit despite radiological improvement 8. The TIME3 trial demonstrated that while urokinase improved secondary outcomes (pleural opacity reduction, shorter hospital stay), it did not improve dyspnea scores or pleurodesis success rates 8.

Critical Context for Your Patient

For a breast cancer patient with lung metastases:

1. Bleeding risk is amplified if there is tumor invasion of pleural vessels or if the patient requires anticoagulation
2. Recurrence of loculations occurs in 41% of patients with indwelling pleural catheters despite fibrinolytic therapy 8, 2
3. The 2023 British Thoracic Society guideline recommends intrapleural fibrinolytics only in "highly selected symptomatic patients" and notes their use "should be limited to highly selected cases and research studies" 9

Risk Mitigation

To minimize complications:

• Avoid intramuscular injections and unnecessary venipunctures during therapy 1
• Monitor all potential bleeding sites carefully
• Discontinue therapy immediately if serious bleeding occurs 1
• Have volume replacement and blood products readily available
• Consider contraindications carefully, particularly recent surgery, coagulopathy, or concurrent anticoagulation 1
• Use antipyretics that don't inhibit platelet function (avoid NSAIDs and aspirin) 1

The evidence suggests that while fibrinolytics can improve fluid drainage and radiological appearance in 60-100% of cases 8, the lack of improvement in patient-centered outcomes like dyspnea, combined with the 3-8.5% risk of significant bleeding, makes this a high-risk intervention with questionable clinical benefit in malignant pleural effusion.